Literature DB >> 15004575

Five to 15 year follow-up of resolved idiopathic central serous chorioretinopathy.

R Wong1, A Chopdar, M Brown.   

Abstract

PURPOSE: To recognize the long-term sequelae of resolved idiopathic central serous chorioretinopathy (ICSC) in relation to visual acuity, contrast sensitivity, and lesion size between time elapsed since disease onset.
METHODS: Patients were recruited from fluorescein angiogram records between January 1985 and December 1995 with confirmed ICSC. Visual acuity, contrast sensitivity, and digital fundus photographs were recorded on follow-up. Comparison with the initial red-free photographs were made.
RESULTS: There was no statistically significant deterioration of visual acuity over time compared to eyes with ICSC after initial resolution and the normal eyes. The change of lesion size over time was also statistically insignificant. Contrast sensitivity compared to visual acuity showed positive correlation in both ICSC and normal eyes, but the results were statistically insignificant. Lesion size correlates negatively with visual acuity and contrast sensitivity although this was statistically insignificant.
CONCLUSION: This study shows little, if any, correlation between time and progression of retinal pigment epitheliopathy following resolution of ICSC. Visual acuity did not seem to worsen over time. Our data were not statistically significant, but it does give insight into the natural history of what is still a relatively poorly understood disease.

Entities:  

Mesh:

Year:  2004        PMID: 15004575     DOI: 10.1038/sj.eye.6700637

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  11 in total

1.  [Central serous chorioretinopathy (CSC)].

Authors:  H Baraki; N Feltgen; J Roider; H Hoerauf; C Klatt
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

2.  Role of Transpupillary Thermotherapy in Central Serous Chorio-Retinopathy.

Authors:  V Mathur; Jks Parihar; R Maggon; S K Mishra
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 3.  [Statement and recommendation of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Situation January 2018].

Authors: 
Journal:  Ophthalmologe       Date:  2018-05       Impact factor: 1.059

4.  A missense variant in FGD6 confers increased risk of polypoidal choroidal vasculopathy.

Authors:  Lulin Huang; Houbin Zhang; Ching-Yu Cheng; Feng Wen; Pancy O S Tam; Peiquan Zhao; Haoyu Chen; Zheng Li; Lijia Chen; Zhengfu Tai; Kenji Yamashiro; Shaoping Deng; Xianjun Zhu; Weiqi Chen; Li Cai; Fang Lu; Yuanfeng Li; Chui-Ming G Cheung; Yi Shi; Masahiro Miyake; Yin Lin; Bo Gong; Xiaoqi Liu; Kar-Seng Sim; Jiyun Yang; Keisuke Mori; Xiongzhe Zhang; Peter D Cackett; Motokazu Tsujikawa; Kohji Nishida; Fang Hao; Shi Ma; He Lin; Jing Cheng; Ping Fei; Timothy Y Y Lai; Sibo Tang; Augustinus Laude; Satoshi Inoue; Ian Y Yeo; Yoichi Sakurada; Yu Zhou; Hiroyuki Iijima; Shigeru Honda; Chuntao Lei; Lin Zhang; Hong Zheng; Dan Jiang; Xiong Zhu; Tien-Ying Wong; Chiea-Chuen Khor; Chi-Pui Pang; Nagahisa Yoshimura; Zhenglin Yang
Journal:  Nat Genet       Date:  2016-04-18       Impact factor: 38.330

5.  The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy.

Authors:  Ji Won Lim; Su Jeong Ryu; Min Cheol Shin
Journal:  Korean J Ophthalmol       Date:  2010-06-05

6.  Factors influencing the visual acuity of chronic central serous chorioretinopathy.

Authors:  Yun Young Kim; Christina J Flaxel
Journal:  Korean J Ophthalmol       Date:  2011-03-11

7.  Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial.

Authors:  Myrte B Breukink; Susan M Downes; Giuseppe Querques; Elon H C van Dijk; Anneke I den Hollander; Rocio Blanco-Garavito; Jan E E Keunen; Eric H Souied; Robert E MacLaren; Carel B Hoyng; Sascha Fauser; Camiel J F Boon
Journal:  Trials       Date:  2015-09-21       Impact factor: 2.279

8.  The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy.

Authors:  Dong Yoon Kim; Soo Geun Joe; Sung Jae Yang; Joo Yong Lee; June-Gone Kim; Young Hee Yoon
Journal:  Korean J Ophthalmol       Date:  2015-05-20

9.  Factors affecting the visual outcome in acute central serous chorioretinopathy.

Authors:  Qamar Ul Islam; Muhammad Asad Farooq; Mohammad Asim Mehboob
Journal:  Pak J Med Sci       Date:  2017 Jan-Feb       Impact factor: 1.088

10.  Pattern of Contrast Sensitivity Changes in Acute Central Serous Chorioretinopathy.

Authors:  Preeyachan Lourthai; Patama Bhurayanontachai
Journal:  J Ophthalmol       Date:  2017-12-20       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.